N,O-diacetyl-D,L-serine | 89826-76-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,O-diacetyl-D,L-serine
• 英文别名: N,O-diacetyl-serine；N,O-Diacetyl-serin；N,O-diacetylserine；O,N-Diacetyl-DL-serin；3-(Acetyloxy)-2-acetamidopropanoic acid；2-acetamido-3-acetyloxypropanoic acid
• CAS: 89826-76-6
• 化学式: C₇H₁₁NO₅
• 分子量: 189.168
• InChiKey: PTARIFVUPQMDHN-UHFFFAOYSA-N

物化性质

• 熔点：
  99 °C
• 沸点：
  454.2±40.0 °C(Predicted)
• 密度：
  1.273±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  92.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N,O-diacetyl-D,L-serine 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 3-acetoxymethyl-5-methyl-[1,2,4]oxadiazole
  参考文献：
  名称：

  Chow, Yuan L.; Polo, Joel S., Journal of the Chemical Society. Perkin transactions II, 1986, p. 727 - 734

  摘要：

  DOI：
• 作为产物：
  描述：

  DL-丝氨酸 、 乙酸酐 在 sodium hydroxide 作用下， 生成 N,O-diacetyl-D,L-serine
  参考文献：
  名称：

  Isolation of acetylseryltyrosine from the chymotryptic digests of proteins of five strains of tobacco mosaic virus

  摘要：

  DOI：

  10.1016/0006-3002(58)90060-x

文献信息

• The facile synthesis of a series of tryptophan derivatives
  作者：Georg Blaser、John M. Sanderson、Andrei S. Batsanov、Judith A.K. Howard

  DOI：10.1016/j.tetlet.2008.02.120

  日期：2008.4

  of 5- and 6-substituted tryptophan derivatives that are difficult to prepare using alternative enzymatic approaches. Acylation of an activated amino acid, derived from serine in situ, is coupled with an enzymatic resolution step to furnish enantiopure analogues bearing a range of electron withdrawing and releasing substituents. Isolation of a dehydroalanine derivative as a by-product from some reactions

  这项研究报告了一种简便的方法，用于合成各种5和6取代的色氨酸衍生物，这些色素很难使用替代酶方法制备。原位衍生自丝氨酸的活化氨基酸的酰化与酶促拆分步骤相结合，以提供带有一系列吸电​​子和释放电子的取代基的对映纯类似物。从某些反应中分离出作为副产物的脱氢丙氨酸衍生物，可为该反应的可能机理提供一些见解。
• Rearrangement of carboxylates derived from N-acetyl-N-nitroso -α-amino-acids
  作者：Yuan L. Chow、Joël Polo

  DOI：10.1039/c39810000297

  日期：——

  While N-acetyl-N-nitrosophenylalanine thermally decomposes by the known mechanism, its carboxylate anion undergoes facile rearrangements initiated by carboxylate attack in methanol or water to give 2-methoxy- or 2-hydroxy-3-phenylpropanoic acid, respectively.

  而Ñ乙酰基Ñ -nitrosophenylalanine热分解通过已知的机构，其羧酸根阴离子经历容易的通过在甲醇或水中羧酸攻击开始，得到2-甲氧基或2-羟基-3-苯基丙酸，分别重排。
• PEG LINKER COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES THEREOF
  申请人：Lee Chyi

  公开号：US20090285780A1

  公开（公告）日：2009-11-19

  PEG linker compounds and biologically active conjugates thereof having mixed functional group linkages attached to at least one PEG moeity, and a coupling group for attaching a biologically active molecule. The PEG mixed linkages can be the combinations of stable, or labile, or releasable, or stable and labile, or stable and releasable, or releasable and labile covalent linkages. The mixed functional linkages of the PEG linker compounds consist of different organic functional groups, which have non-equivalent half-life in plasma and, hence, they have different release rates in blood. The present invention also provides for attachment of novel PEG linker compounds with mixed functional linkages for Pegylation of biologically active molecules to produce Probiomolecule-PEG constructs. The Probiomolecule-PEG construct is the prodrug of biomolecule-PEG conjugate or biomolecule. The Probiomolecule-PEG conjugate will gradually lose portions (or all) of its PEG polymers in vivo to convert into smaller size biomolecule-PEG conjugate (or biologically active molecule), thereby increasing their biological activity in vivo.

  PEG连接剂化合物及其生物活性共轭物，其混合功能基连接至少一个PEG分子，并具有用于连接生物活性分子的偶联基。PEG混合连接可以是稳定的、不稳定的、可释放的、稳定和不稳定的、稳定和可释放的、可释放和不稳定的共价连接的组合。PEG连接剂的混合功能连接由不同的有机功能基组成，在血浆中具有不同的半衰期，因此在血液中具有不同的释放速率。本发明还提供了将新型PEG连接剂与混合功能连接用于PEG化生物活性分子，以产生Probiomolecule-PEG构建物的附着。Probiomolecule-PEG构建物是生物分子-PEG共轭物或生物分子的前药。Probiomolecule-PEG共轭物将逐渐失去其体内的PEG聚合物部分（或全部），转化为更小的生物分子-PEG共轭物（或生物活性分子），从而增加它们在体内的生物活性。
• Methods of use for novel sulfur containing organic nitrate compounds
  申请人：NitroMed, Inc.

  公开号：US20040152753A1

  公开（公告）日：2004-08-05

  The invention describes methods of use for an organic nitrate compound, or a pharmaceutically acceptable salt thereof, wherein the organic nitrate compound comprises at least one sulfur atom and/or at least one disulfide group. The invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; for decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating and/or preventing gastrointestinal disorders; for treating inflammatory disease states and disorders; for treating and/or preventing ophthalmic diseases or disorders; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; for decreasing the recurrence of ulcers; for improving gastroprotective properties, anti- Helicobacter pylori properties or antacid properties of proton pump inhibitors; for treating Helicobacter pylori and viral infections; for improving gastroprotective properties of H 2 receptor antagonists; for treating and/or preventing inflammations and microbial infections, multiple sclerosis, and viral infections; for treating or preventing restenosis, autoimmune diseases, pathological conditions resulting from abnormal cell proliferation, polycystic kidney disease, inflammatory diseases or to inhibit wound contraction; for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females; for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, and overactive bladder; for reversing the state of anesthesia; for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3′,5′-monophosphate (cGMP); for treating respiratory disorders and for treating neurological conditions.

  本发明描述了有机硝酸盐化合物或其药学上可接受的盐的使用方法，其中有机硝酸盐化合物包含至少一个硫原子和/或至少一个二硫化物基团。本发明还提供了治疗、预防和/或减轻炎症、疼痛和发热的方法；减少或逆转因使用非甾体抗炎化合物而导致的胃肠道、肾脏和其他毒性的方法；治疗和/或预防胃肠道紊乱的方法；治疗炎症性疾病状态和紊乱的方法；用于治疗和/或预防眼科疾病或失调；用于治疗和/或改善 COX-2 抑制剂的胃肠道特性；用于促进伤口愈合；用于治疗和/或预防因环氧化酶-2 水平升高而导致的其他失调；用于减少溃疡复发；用于改善胃肠道保护特性、抗幽门螺旋杆菌、治疗和/或预防眼科疾病或失调。 幽门螺旋杆菌 质子泵抑制剂的胃保护特性、抗幽门螺旋杆菌特性或抗酸特性；治疗 幽门螺旋杆菌 和病毒感染；改善 H 2 受体拮抗剂；治疗和/或预防炎症和微生物感染、多发性硬化症和病毒感染；治疗或预防再狭窄、自身免疫性疾病、细胞异常增殖引起的病理状况、多囊肾、炎症性疾病或抑制伤口收缩；治疗或预防男性和女性的性功能障碍，增强男性和女性的性反应；用于治疗或预防良性前列腺增生症、高血压、充血性心力衰竭、变异型（Printzmetal）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、急迫性尿失禁和膀胱过度活动症；用于逆转麻醉状态；治疗或预防因环鸟苷-3′,5′-单磷酸（cGMP）代谢增加而诱发的疾病；治疗呼吸系统疾病和神经系统疾病。
• Nitratoalkancarbonsäure-Derivate und Verfahren zu ihrer Herstellung
  申请人：SCHWARZ PHARMA AG

  公开号：EP0451760B1

  公开（公告）日：1995-09-13